JAC Advance Access originally published online on September 1, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy (2003) 52, 679-682
© 2003 The British Society for Antimicrobial Chemotherapy
The European Confederation of Medical Mycology ECMM) survey of candidaemia in Italy: antifungal susceptibility patterns of 261 non-albicans Candida isolates from blood
Istituto di Igiene e Medicina Preventiva, Università degli Studi – IRCCS Ospedale Maggiore di Milano, via F. Sforza 35, 20122 Milano, Italy
Received 14 April 2003; returned 23 May 2003; revised 17 June 2003; accepted 26 June 2003
Objectives: To analyse the in vitro antifungal susceptibility of 261 non-albicans Candida bloodstream strains isolated during the European Confederation of Medical Mycology survey of candidaemia performed in Lombardia, Italy (September 1997–December 1999).
Methods: In vitro susceptibility to flucytosine, fluconazole, itraconazole, posaconazole and voriconazole was determined using the broth microdilution method described in the NCCLS M27-A guidelines. Etest strips were used to assess susceptibility to amphotericin B. In vitro findings were correlated with the patient’s underlying condition and previous antifungal treatment.
Results: MICs (mg/L) at which 90% of the strains were inhibited were, respectively, 2 for flucytosine, 8 for fluconazole, 0.5 for itraconazole, 0.25 for voriconazole and 0.25 for posaconazole. Amphotericin B MIC endpoints were <0.50 mg/L in all the isolates tested. Flucytosine resistance was detected in 19 isolates (7%), mainly among Candida tropicalis strains (30%). Innate or secondary fluconazole resistance was detected in 13 strains (5%). Among the 13 patients with fluconazole-resistant Candida bloodstream infection, three were HIV positive, including one treated with fluconazole for oral candidosis; the four who were HIV negative had received the azole during the 2 weeks preceding the candidaemia. Cross-resistance among fluconazole and other azoles was a rare event.
Conclusions: Resistance is still uncommon in non-albicans Candida species recovered from blood cultures. However, in fungaemias caused by C. tropicalis, Candida glabrata and Candida krusei, there is a high prevalence of resistance to fluconazole and flucytosine. Fluconazole resistance should be suspected in patients treated previously with azoles, mainly those with advanced HIV infection.
Keywords: flucytosine, fluconazole, itraconazole, posaconazole, voriconazole
* Corresponding author. Tel: +39-02-55033487/+39-02-50320600; Fax: +39-02-50320597; E-mail: annamaria.tortorano{at}unimi.it
The FIMUA-ECMM candidaemia study group are listed in the Acknowledgements.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. Trofa, A. Gacser, and J. D. Nosanchuk Candida parapsilosis, an Emerging Fungal Pathogen Clin. Microbiol. Rev., October 1, 2008; 21(4): 606 - 625. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Pfaller, D. J. Diekema, G. W. Procop, and M. G. Rinaldi Multicenter Comparison of the VITEK 2 Antifungal Susceptibility Test with the CLSI Broth Microdilution Reference Method for Testing Amphotericin B, Flucytosine, and Voriconazole against Candida spp. J. Clin. Microbiol., November 1, 2007; 45(11): 3522 - 3528. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Fleck, A. Dietz, and H. Hof In vitro susceptibility of Candida species to five antifungal agents in a German university hospital assessed by the reference broth microdilution method and Etest J. Antimicrob. Chemother., April 1, 2007; 59(4): 767 - 771. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. L. R. da Matta, M. d. S. C. Melhem, A. L. Colombo, M. L. Moretti, L. Rodero, G. M. D. de Almeida, M. d. A. Martins, S. F. Costa, M. B. G. Souza Dias, M. Nucci, et al. Antifungal Drug Susceptibility Profile of Pichia anomala Isolates from Patients Presenting with Nosocomial Fungemia Antimicrob. Agents Chemother., April 1, 2007; 51(4): 1573 - 1576. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Pfaller, D. J. Diekema, G. W. Procop, and M. G. Rinaldi Multicenter Comparison of the VITEK 2 Yeast Susceptibility Test with the CLSI Broth Microdilution Reference Method for Testing Fluconazole against Candida spp. J. Clin. Microbiol., March 1, 2007; 45(3): 796 - 802. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Pfaller and D. J. Diekema Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem Clin. Microbiol. Rev., January 1, 2007; 20(1): 133 - 163. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Pfaller, D. J. Diekema, M. Mendez, C. Kibbler, P. Erzsebet, S.-C. Chang, D. L. Gibbs, V. A. Newell, and the Global Antifungal Surveillance Group Candida guilliermondii, an Opportunistic Fungal Pathogen with Decreased Susceptibility to Fluconazole: Geographic and Temporal Trends from the ARTEMIS DISK Antifungal Surveillance Program J. Clin. Microbiol., October 1, 2006; 44(10): 3551 - 3556. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-W. Chen, Y.-C. Chen, H.-J. Lo, F. C. Odds, T.-H. Wang, C.-Y. Lin, and S.-Y. Li Multilocus Sequence Typing for Analyses of Clonality of Candida albicans Strains in Taiwan J. Clin. Microbiol., June 1, 2006; 44(6): 2172 - 2178. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Pfaller, D. J. Diekema, and D. J. Sheehan Interpretive Breakpoints for Fluconazole and Candida Revisited: a Blueprint for the Future of Antifungal Susceptibility Testing Clin. Microbiol. Rev., April 1, 2006; 19(2): 435 - 447. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Charlier, E. Hart, A. Lefort, P. Ribaud, F. Dromer, D. W. Denning, and O. Lortholary Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? J. Antimicrob. Chemother., March 1, 2006; 57(3): 384 - 410. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Vandeputte, G. Larcher, T. Berges, G. Renier, D. Chabasse, and J.-P. Bouchara Mechanisms of Azole Resistance in a Clinical Isolate of Candida tropicalis Antimicrob. Agents Chemother., November 1, 2005; 49(11): 4608 - 4615. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Almirante, D. Rodriguez, B. J. Park, M. Cuenca-Estrella, A. M. Planes, M. Almela, J. Mensa, F. Sanchez, J. Ayats, M. Gimenez, et al. Epidemiology and Predictors of Mortality in Cases of Candida Bloodstream Infection: Results from Population-Based Surveillance, Barcelona, Spain, from 2002 to 2003 J. Clin. Microbiol., April 1, 2005; 43(4): 1829 - 1835. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K.-W. Chen, H.-J. Lo, Y.-H. Lin, and S.-Y. Li Comparison of four molecular typing methods to assess genetic relatedness of Candida albicans clinical isolates in Taiwan J. Med. Microbiol., March 1, 2005; 54(3): 249 - 258. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Pfaller, S. A. Messer, L. Boyken, S. Tendolkar, R. J. Hollis, and D. J. Diekema Geographic Variation in the Susceptibilities of Invasive Isolates of Candida glabrata to Seven Systemically Active Antifungal Agents: a Global Assessment from the ARTEMIS Antifungal Surveillance Program Conducted in 2001 and 2002 J. Clin. Microbiol., July 1, 2004; 42(7): 3142 - 3146. [Abstract] [Full Text] [PDF]
|
|